Caliway Biopharmaceuticals, a Taiwan-based biopharmaceutical company, announced on Monday that it has completed enrolment of subjects in the CBL-0201EFP Phase 2-stage 2 study.
The study, an open-label trial, is intended to assess the efficacy, safety, and tolerability of CBL-0201EFP in treating subjects with moderate to severe cellulite.
A total of 23 subjects were enrolled in the study and all are to receive the CBL-514 treatment. The efficacy and safety of the trial is to be assessed at follow-up visits at week four and week 13 after the last treatment. The study's topline outcome is expected to be revealed in the second quarter of 2024.
The company says that the product is a first-in-class small-molecule drug and is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to decrease subcutaneous adiposity in treatment areas in animal studies without causing any systematic side impacts on the central nervous system, cardiovascular system and respiratory system.
NRx Pharmaceuticals and HOPE Therapeutics align with FDA on Pediatric Study Plan for NRX-100
ToxStrategies acquires Clintrex Research
TPG invests in K2 Medical Research to expand clinical trial site platform
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain